Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2011, Article ID 918017, 11 pages
http://dx.doi.org/10.4061/2011/918017
Review Article

Treatment of Hepatitis B in Decompensated Liver Cirrhosis

1Mount Elizabeth Hospital and Medical Centre, Singapore 228510
2Gleneagles Hospital and Medical Centre, Singapore 258500

Received 15 February 2011; Accepted 19 April 2011

Academic Editor: Deepak Amarapurkar

Copyright © 2011 Richard Guan and Hock Foong Lui. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. E. Mast, M. J. Alter, and H. S. Margolis, “Strategies to prevent and control hepatitis B and C virus infections: a global perspectiveStrategies to prevent and control hepatitis B and C virus infections: a global perspective,” Vaccine, vol. 17, no. 13-14, pp. 1730–1733, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. G. M. McQuillan, P. J. Coleman, D. Kruszon-Moran, L. A. Moyer, S. B. Lambert, and H. S. Margolis, “Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition examination surveys, 1976 through 1994,” American Journal of Public Health, vol. 89, no. 1, pp. 14–18, 1999. View at Google Scholar · View at Scopus
  3. F. E. De Jongh, H. L. A. Janssen, R. A. De Man, W. C. J. Hop, S. W. Schalm, and M. Van Blankenstein, “Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver,” Gastroenterology, vol. 103, no. 5, pp. 1630–1635, 1992. View at Google Scholar · View at Scopus
  4. G. Fattovich, L. Brollo, G. Giustina et al., “Natural history and prognostic factors for chronic hepatitis B,” Gut, vol. 32, no. 3, pp. 294–298, 1991. View at Google Scholar · View at Scopus
  5. D. Samuel, R. Muller, G. Alexander et al., “Liver transplantation in European patients with the hepatitis B surface antigen,” New England Journal of Medicine, vol. 329, no. 25, pp. 1842–1847, 1993. View at Publisher · View at Google Scholar · View at Scopus
  6. X. M. Lin, N. Robinson, M. Thursz et al., “Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression,” Journal of Gastroenterology and Hepatology, vol. 20, pp. 833–843, 2005. View at Google Scholar
  7. I. D. Gust, “Epidemiology of hepatitis B infection in the Western Pacific and South East Asia,” Gut, vol. 38, supplement 2, no. 2, pp. S18–S23, 1996. View at Google Scholar · View at Scopus
  8. A. S. Lok, “Natural history and control of perinatally acquired hepatitis B virus infection,” Digestive Diseases, vol. 10, no. 1, pp. 46–52, 1992. View at Google Scholar · View at Scopus
  9. D. S. Chen, “Natural history of chronic hepatitis B virusinfection: new light on an old story,” Journal of Gastroenterology and Hepatology, vol. 8, pp. 470–475, 1993. View at Google Scholar
  10. C. M. Chu, P. Karayiannis, and M. J. F. Fowler, “Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum,” Hepatology, vol. 5, no. 3, pp. 431–434, 1985. View at Google Scholar · View at Scopus
  11. E. R. Schiff, M. F. Sorrell, and W. C. Maddrey, Diseases of the Liver, Lippincott Williams &Wilkins, Haggerstown, Md, USA, 8th edition, 1999.
  12. P. Marcellin, M. Martinot-Peignoux, M. A. Loriot et al., “Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy,” Annals of Internal Medicine, vol. 112, no. 3, pp. 227–228, 1990. View at Google Scholar · View at Scopus
  13. S. Kaneko, R. H. Miller, A. M. Di Bisceglie, S. M. Feinstone, J. H. Hoofnagle, and R. H. Purcell, “Detection of hepatitis B virus DNA in serum by polymerase chain reaction: application for clinical diagnosis,” Gastroenterology, vol. 99, no. 3, pp. 799–804, 1990. View at Google Scholar · View at Scopus
  14. C. M. Chu and Y. F. Liaw, “Hepatitis B virus-related cirrhosis: natural history and treatment,” Seminars in Liver Disease, vol. 26, no. 2, pp. 142–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Xu, D. C. Hu, D. M. Rosenberg et al., “Chronic Hepatitis B—a long term retrospective cohort study of disease progression in Shanghai, China,” Journal of Gastroenterology and Hepatology, vol. 18, no. 12, pp. 1345–1352, 2003. View at Google Scholar
  16. Y. F. Liaw, D. Y. Lin, T. J. Chen, and C. M. Chu, “Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study,” Liver, vol. 9, no. 4, pp. 235–241, 1989. View at Google Scholar · View at Scopus
  17. I. Okazaki, K. Maruyama, and K. Funatsu, “Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis,” Gastroenterologia Japonica, vol. 15, no. 4, pp. 350–354, 1980. View at Google Scholar
  18. A. Y. Hui, H. L. Y. Chan, N. W. Y. Leung, L. C. T. Hung, F. L. Chan, and J. J. Y. Sung, “Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation,” Journal of Clinical Gastroenterology, vol. 34, no. 5, pp. 569–572, 2002. View at Publisher · View at Google Scholar
  19. F. Donato, A. Tagger, R. Chiesa et al., “Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy,” Hepatology, vol. 26, no. 3, pp. 579–584, 1997. View at Google Scholar · View at Scopus
  20. K. Krogsgaard, B. O. Lindhardt, and J. O. Nielsen, “The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers,” Hepatology, vol. 7, no. 1, pp. 37–41, 1987. View at Google Scholar · View at Scopus
  21. V. K. Rustgi, J. H. Hoofnagle, and J. L. Gerin, “Hepatitis B virus infection in the acquired immunodeficiency syndrome,” Annals of Internal Medicine, vol. 101, no. 6, pp. 795–797, 1984. View at Google Scholar · View at Scopus
  22. Y. F. Liaw, “Role of hepatitis C virus in dual and triple hepatitis virus infection,” Hepatology, vol. 22, no. 4 I, pp. 1101–1108, 1995. View at Google Scholar · View at Scopus
  23. L. Benvegnu, G. Fattovich, F. Noventa et al., “Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study,” Cancer, vol. 74, no. 9, pp. 2442–2448, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Fattovich, G. Giustina, E. Christensen et al., “Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B,” Gut, vol. 46, no. 3, pp. 420–426, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Tur-Kaspa, Y. Shaul, D. D. Moore et al., “The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer,” Virology, vol. 167, no. 2, pp. 630–633, 1988. View at Google Scholar · View at Scopus
  26. J. S. McMillan, T. Shaw, P. W. Angus, and S. A. Locarnini, “Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro,” Hepatology, vol. 22, no. 1, pp. 36–43, 1995. View at Google Scholar · View at Scopus
  27. Y. F. Liaw, D. I. Tai, C. M. Chu, and T. J. Chen, “The development of cirrhosis in patients with chronic type B hepatitis: a prospective study,” Hepatology, vol. 8, no. 3, pp. 493–496, 1988. View at Google Scholar · View at Scopus
  28. P. S. Kamath, R. H. Wiesner, M. Malinchoc et al., “A model to predict survival in patients with end-stage liver disease,” Hepatology, vol. 33, no. 2, pp. 464–470, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. E. B. Keeffe, “Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?” American Journal of Gastroenterology, vol. 90, no. 2, pp. 201–205, 1995. View at Google Scholar · View at Scopus
  30. Centers for Disease Control and Prevention, “Prevention of hepatitis A through active or passive immunization: recommendations of the advisory committee on immunization practices (ACIP),” The MMWR Recommendations and Reports, vol. 45, pp. 1–30, 1996. View at Google Scholar
  31. European Association for the Study of the Liver, “EASL clinical practice guide lines: management of chronic hepatitis B,” Journal of Hepatology, vol. 10, no. 2, pp. 227–242, 2009. View at Google Scholar
  32. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. F. Liaw, N. Leung, J. H. Kao et al., “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update,” Hepatology International, vol. 2, no. 3, pp. 263–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. C. Teran, T. F. Imperiale, K. D. Mullen, A. S. Tavill, and A. J. McCullough, “Primary prophylaxis of variceal bleeding in cirrhotics: a cost-effectiveness analysis,” Gastroenterology, vol. 112, no. 2, pp. 473–482, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. A. I. Sharara and D. C. Rockey, “Gastroesophageal variceal hemorrhage,” New England Journal of Medicine, vol. 345, no. 9, pp. 669–681, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Luca, G. D'Amico, R. La Galla, M. Midiri, A. Morabito, and L. Pagliaro, “TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials,” Radiology, vol. 212, no. 2, pp. 411–421, 1999. View at Google Scholar · View at Scopus
  37. P. Ginès and A. Cárdenas, “The management of ascites and hyponatremia in cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 43–58, 2008. View at Publisher · View at Google Scholar
  38. P. Tandon and G. Garcia-Tsao, “Bacterial infections, sepsis, and multiorgan failure in cirrhosis,” Seminars in Liver Disease, vol. 28, no. 1, pp. 26–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Rössle, A. Ochs, V. Gülberg et al., “A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites,” New England Journal of Medicine, vol. 342, no. 23, pp. 1701–1707, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Córdoba and B. Mínguez, “Hepatic encephalopathy,” Seminars in Liver Disease, vol. 28, no. 1, pp. 70–80, 2008. View at Publisher · View at Google Scholar
  41. V. Arroyo, J. Fernandez, and P. Ginès, “Pathogenesis and treatment of hepatorenal syndrome,” Seminars in Liver Disease, vol. 28, no. 1, pp. 81–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Sherman, K. M. Peltekian, and C. Lee, “Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population,” Hepatology, vol. 22, no. 2, pp. 432–438, 1995. View at Google Scholar · View at Scopus
  43. E. B. Keeffe, “Liver transplantation: current status and novel approaches to liver replacement,” Gastroenterology, vol. 120, no. 3, pp. 749–762, 2001. View at Google Scholar · View at Scopus
  44. E. C. Seaberg, S. H. Belle, K. C. Beringer, J. L. Schivins, and K. M. Detre, “Liver transplantation in the United States from 1987–998: updated results from the PITT-UNOS liver transplant registry,” in Clinical Transplants 1998, J. M. Cecka and P. I. Terasaki, Eds., pp. 17–37, UCLA Tissue Typing Laboratory, Los Angeles, Calif, USA, 1999. View at Google Scholar
  45. D. Shouval and D. Samuel, “Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review,” Hepatology, vol. 32, no. 6, pp. 1189–1195, 2000. View at Google Scholar · View at Scopus
  46. R. P. Perrillo, E. R. Schiff, G. L. Davis et al., “A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B,” New England Journal of Medicine, vol. 323, no. 5, pp. 295–301, 1990. View at Google Scholar · View at Scopus
  47. D. K. H. Wong, A. M. Cheung, K. O'Rourke, C. D. Naylor, A. S. Detsky, and J. Heathcote, “Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis,” Annals of Internal Medicine, vol. 119, no. 4, pp. 312–323, 1993. View at Google Scholar · View at Scopus
  48. J. H. Hoofnagle, A. M. Di Bisceglie, J. G. Waggoner, and Y. Park, “Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B,” Gastroenterology, vol. 104, no. 4, pp. 1116–1121, 1993. View at Google Scholar · View at Scopus
  49. R. Perrillo, C. Tamburro, F. Regenstein et al., “Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus,” Gastroenterology, vol. 109, no. 3, pp. 908–916, 1995. View at Publisher · View at Google Scholar · View at Scopus
  50. R. J. Fontana, “Management of patients with decompensated HBV cirrhosis,” Seminars in Liver Disease, vol. 23, no. 1, pp. 89–100, 2003. View at Google Scholar · View at Scopus
  51. R. Fontana, H. W. L. Hann, R. P. Perrillo et al., “Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy,” Gastroenterology, vol. 123, no. 3, pp. 719–727, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. E. R. Schiff, C. L. Lai, S. Hadziyannis et al., “Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients,” Hepatology, vol. 38, no. 6, pp. 1419–1427, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Schiff, C. L. Lai, S. Hadziyannis et al., “Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results,” Liver Transplantation, vol. 13, no. 3, pp. 349–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. J. L. Dienstag, E. R. Schiff, T. L. Wright et al., “Lamivudine as initial treatment for chronic hepatitis B in the United States,” New England Journal of Medicine, vol. 341, no. 17, pp. 1256–1263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. C. L. Lai, R. N. Chien, N. W. Y. Leung et al., “A one-year trial of lamivudine for chronic hepatitis B,” New England Journal of Medicine, vol. 339, no. 2, pp. 61–68, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. N. W. Y. Leung, C. L. Lai, T. T. Chang et al., “Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy,” Hepatology, vol. 33, no. 6, pp. 1527–1532, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. M. I. Allen, M. Deslauriers, C. Webster Andrews et al., “Identification and characterization of mutations in hepatitis B virus resistant to lamivudine,” Hepatology, vol. 27, no. 6, pp. 1670–1677, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Melegari, P. P. Scaglioni, and J. R. Wands, “Hepatitis B virus mutants associated with 3TC and Famciclovir administration are replication defective,” Hepatology, vol. 27, no. 2, pp. 628–633, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. F. Liaw, R. N. Chien, C. T. Yeh, S. L. Tsai, and C. M. Chu, “Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy,” Hepatology, vol. 30, no. 2, pp. 567–572, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. J. P. Villeneuve, L. D. Condreay, B. Willems et al., “Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B,” Hepatology, vol. 31, no. 1, pp. 207–210, 2000. View at Google Scholar · View at Scopus
  61. D. Kapoor, R. C. Guptan, S. M. Wakil et al., “Beneficial effects of lamivudine in hepatitis b virus-related decompensated cirrhosis,” Journal of Hepatology, vol. 33, no. 2, pp. 308–312, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Y. Yao and N. M. Bass, “Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis b infection,” Journal of Hepatology, vol. 33, no. 2, pp. 301–307, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Manolakopoulos, S. Karatapanis, T. Elefsiniotis et al., “Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to hepatitis BeAg negative chronic HBV infection,” American Journal of Gastroenterology, vol. 99, pp. 57–63, 2003. View at Google Scholar
  64. R. P. Perrillo, T. Wright, J. Rakela et al., “A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B,” Hepatology, vol. 33, no. 2, pp. 424–432, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Y. Yao, N. A. Terrault, C. Freise, L. Maslow, and N. M. Bass, “Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort,” Hepatology, vol. 34, no. 2, pp. 411–416, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Fontana, E. B. Keeffe, W. Carey et al., “Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B,” Liver Transplantation, vol. 8, no. 5, pp. 433–439, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Kitay-Cohen, Z. Ben-Ari, R. Tur-Kaspa, H. Fainguelernt, and M. Lishner, “Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis,” Transplantation, vol. 69, no. 11, pp. 2382–2383, 2000. View at Google Scholar · View at Scopus
  68. Y. F. Liaw , M. Raprapoulou-Glgi, H. Chemquer, S. K. Sann, T. Tanwandee, N. Leung et al., “Efficacy, safety of entecavir versus adefovir In chronic hepatitis B patients with evidence of hepatic decompensation,” Journal of Hepatology, vol. 50, p. 505A, 2009. View at Google Scholar
  69. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-tern therapy With adefovir dipivoxil in HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar
  70. H. Izzedine, V. Launay-Vacher, and G. Deray, “Antiviral drug-induced nephrotoxicity,” American Journal of Kidney Diseases, vol. 45, no. 5, pp. 804–817, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. C. L. Lai, N. Leung, E. K. Teo et al., “A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B,” Gastroenterology, vol. 129, no. 2, pp. 528–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. E. J. Gane, H. L. Chan, G. Choudhuri et al., “Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine,” Journal of Hepatology, vol. 52, supplement 1, p. S4, 2010. View at Google Scholar
  73. R. A. De Man, L. M. M. Wolters, F. Nevens et al., “Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection,” Hepatology, vol. 34, no. 3, pp. 578–582, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Levine, D. Hernandez, G. Yamanaka et al., “Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 8, pp. 2525–2532, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. I. T. Chang, R. G. Gish, R. DcMan et al., “A comparison of entecavir and lamivudine tor HBeAg-positive chronic hepatitis B,” New England Journal of Medicine, vol. 345, pp. 1001–1010, 2006. View at Google Scholar
  76. N. Leung, C. Y. Peng, H. W. Hann et al., “Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir,” Hepatology, vol. 49, no. 1, pp. 72–79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. D. J. Tenney, R. E. Rose, C. J. Baldick et al., “Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years-of therapy,” Hepatology, vol. 49, no. 5, pp. 1503–1514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. O. Shakil, L. Lilly, P. Angus et al., “Entecavir reduces viral load in liver transplant patients who failed prophylaxis or treatment for hepatitis B,” Journal of Hepatology, vol. 34, abstract 619A, 2001. View at Google Scholar
  79. J. H. Shim, H. C. Lee, K. M. Kim et al., “Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis,” Journal of Hepatology, vol. 52, no. 2, pp. 176–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. S. Seo, F. S. Jung, J. H. Kim et al., “Lamivudine versus entecavir in patients with hepatitis B virus related decompensated liver cirrhosis,” Journal of Hepatology, vol. 50, abstract 550A, 2010. View at Google Scholar
  81. A. M. Peilirelli, G. Barbarim, M. Romano, C. Furlan, A. Paffettl, and R. Villam, “Entecavlr therapy tor lamlvudme resistant HBV cirrhotic patients waiting tor OLT: viral, biochemical outcomes at one year,” Journal of Hepatology, vol. 50, abstract S14A, 2009. View at Google Scholar
  82. Y. F. Liaw, C. Lee, U. S. Akarc, P. V. George, F. Wong et al., “Interim results of a double-blind, randomized phase 2 study of the safety of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxil fumarate, and entecavir in the treatment of chronic hepatitis B subjects with decompensated Liver disease,” Hepatology, vol. 50, abstract 222, 2009. View at Google Scholar
  83. C. M. Lange, J. Bojunga, W. P. Hofmann et al., “Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function,” Hepatology, vol. 50, no. 6, pp. 2001–2006, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. J. S. James, “Tenofovir approved: broad indication,” AIDS Treatment News, no. 373, pp. 2–3, 2001. View at Google Scholar · View at Scopus
  85. J. Heathcote, E. J. Gane, R. A. De Man et al., “Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg positive patients with chronic hepatitis B (Study 103): a preliminary analysis,” Hepatology, vol. 50, abstract 556A, 2010. View at Google Scholar
  86. J. Gallant, E. S. Staszewski, A. L. Pozniak, E. Dejesus, M. Sulellnan, M. D. Millel et al., “Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial,” Journal of the American Medical Association, vol. 292, no. 2, pp. 191–201, 2004. View at Google Scholar
  87. J. G. Rajinders, T. Vries-Slulls, B. E. Hansen, H. L. Zaaijer, M. Prinsj, M. Schumen et al., “Five-year tenotovii therapy is associated with maintained virologic response but significant decline in renal function in HIV-HBV infected patients,” Hepatology, vol. 50, abstract 506A, 2009. View at Google Scholar
  88. C. Constable, K. Childs, M. L. Bachon, D. C. Camero, M. R. Mullen, and D. T. Dieterich, “Does tenofovlr increase the risk of abnormal bone and calcium metabolism?” Hepatology, vol. 51, abstract 518, 2009. View at Google Scholar
  89. E. B. Keeffe, D. T. Dieterich, S. H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. E. J. Gane, P. W. Angus, S. Strasser et al., “Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation,” Gastroenterology, vol. 132, no. 3, pp. 931–937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Angus, S. Strasser, S. Patterson, G. McCaughan, and E. Gane, “A randomized study to assess the safety and efficacy of adefovir dipivoxil,” Hepatology, vol. 46, abstract 238A, 2007. View at Google Scholar
  92. E. Gane, S. Strasser, S. Patterson, G. McCaughan, and P. Angus, “A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates,” Hepatology, vol. 46, abstract 479A, 2007. View at Google Scholar